Shares of Cempra Inc (NASDAQ:CEMP) were down 2.4% during mid-day trading on Monday . The stock traded as low as $17.92 and last traded at $18.02, with a volume of 321,759 shares trading hands. The stock had previously closed at $18.47.

Several analysts have recently issued reports on CEMP shares. JPMorgan Chase & Co. started coverage on shares of Cempra in a research note on Tuesday, July 12th. They set an “overweight” rating and a $31.00 price objective for the company. Stifel Nicolaus decreased their price target on shares of Cempra from $51.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Janney Montgomery Scott decreased their price target on shares of Cempra from $29.00 to $23.00 and set a “neutral” rating for the company in a research report on Monday, May 9th. Cowen and Company reaffirmed a “buy” rating on shares of Cempra in a research report on Friday, June 24th. Finally, Roth Capital began coverage on shares of Cempra in a research report on Tuesday, June 7th. They set a “buy” rating and a $37.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $36.27.

The company’s market cap is $839.64 million. The stock’s 50 day moving average price is $18.19 and its 200 day moving average price is $17.88.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. The business had revenue of $2.70 million for the quarter, compared to analyst estimates of $3.94 million. The firm’s quarterly revenue was down 80.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.41) EPS. Equities research analysts forecast that Cempra Inc will post ($2.58) earnings per share for the current year.

A number of hedge funds and institutional investors have recently modified their holdings of CEMP. General American Investors Co. Inc. boosted its position in shares of Cempra by 190.8% in the fourth quarter. General American Investors Co. Inc. now owns 494,409 shares of the company’s stock worth $15,391,000 after buying an additional 324,409 shares in the last quarter. Tredje AP fonden purchased a new position in shares of Cempra during the fourth quarter worth about $4,981,000. BB Biotech AG boosted its position in shares of Cempra by 5.3% in the fourth quarter. BB Biotech AG now owns 1,991,900 shares of the company’s stock worth $62,008,000 after buying an additional 100,000 shares in the last quarter. Sei Investments Co. boosted its position in shares of Cempra by 717.8% in the fourth quarter. Sei Investments Co. now owns 110,192 shares of the company’s stock worth $3,431,000 after buying an additional 96,718 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Cempra by 427.9% in the fourth quarter. California Public Employees Retirement System now owns 117,200 shares of the company’s stock worth $3,648,000 after buying an additional 95,000 shares in the last quarter.

Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.